HCA Healthcare. has filed a patent for compositions and methods involving biodegradable micro-beads embedding nano-beads with therapeutic agents for imaging and treating diseases, including cancers. The invention aims to provide a more effective and controlled delivery of radiation or chemotherapeutic agents to target tumors. GlobalData’s report on HCA Healthcare gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights HCA Healthcare Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

According to GlobalData’s company profile on HCA Healthcare, Cloud gaming was a key innovation area identified from patents. HCA Healthcare's grant share as of January 2024 was 73%. Grant share is based on the ratio of number of grants to total number of patents.

Cancer treatment micro-beads with nano-beads for targeted therapy

Source: United States Patent and Trademark Office (USPTO). Credit: HCA Healthcare Inc

The patent application (Publication Number: US20240009332A1) describes a novel micro-bead design comprising a matrix and a plurality of nano-beads. These nano-beads can contain various substances such as polymers, radionuclides, chelators, chemotherapeutic agents, metals, color pigments, and cell-penetrating peptides. The matrix of the micro-bead can be made of polymers like polyglycolic acid, polylactic acid, or other materials like collagen, gelatin, glass, or polymethylmethacrylate. The nano-beads within the micro-bead can be biodegradable or non-biodegradable polymers, radionuclides, or other elements like boron-10 or gadolinium-157.

Furthermore, the patent application also includes a method for treating diseases, particularly cancer, in a subject by administering a composition containing these micro-beads. The micro-beads are designed to degrade over a specific period, and when used in cancer treatment, they can target specific types of cancer such as renal cell carcinoma, hepatocellular carcinoma, or metastatic lesions. The method also involves exposing the subject to a neutron source after administering the micro-beads to treat cancer effectively. Overall, the patent application showcases a unique micro-bead design with diverse applications in disease treatment, particularly cancer, highlighting the potential for targeted and effective therapeutic interventions.

To know more about GlobalData’s detailed insights on HCA Healthcare, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies